Retatrutide
Also known as: LY3437943, triple incretin
Early-phase and translational research on retatrutide, a GLP-1/GIP/glucagon tri-agonist in development for obesity and metabolic disease.
What does the research say about Retatrutide?
Retatrutide (LY3437943) is studied as a multi-receptor incretin agonist. The corpus includes phase 1/2 metabolic trials and preclinical receptor pharmacology papers indexed to incretin and obesity MeSH terms.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: Retatrutide
11 indexed papers matched to curated MeSH concepts in the last 90 days.
Retatrutide (LY3437943) for metabolic disorders: A systematic review of clinical outcomes in obesity and type 2 diabetes
This systematic review evaluates retatrutide's effects on weight and glycaemic control in obesity and type 2 diabetes, suggesting its potential in treatment.
Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression
Narrative review highlights the potential of incretin therapies to improve outcomes in liver disease linked to metabolic dysfunction.
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
This review highlights advances in incretin therapies improving metabolic disorders and indicates future research needs.
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide
Novel method synthesizes Retatrutide in a flexible way, suggesting improvement over traditional techniques.
Beyond incretin therapy: integrating precision nutrition for sustained obesity management medications
This conceptual review demonstrates effective obesity management strategies in individuals, suggesting a need for personalized dietary approaches.
Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation
Epicardial adipose tissue-derived kynurenic acid increases AF susceptibility by impairing atrial lymphangiogenesis via GPR35.
May link reduced atrial lymphatics to AF persistence; leaves open whether lymphangiogenic therapies could modify outcomes.
Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?
Next-generation incretin therapies reduce BP, with weight loss driving ~80% of the reduction.
Hypothesis-generating for obese hypertensives; leaves open dedicated RCTs to inform guidelines before adoption.
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
Randomized trials assess changes in lipid and metabolite profiles in obesity, indicating metabolic improvements.
Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists
This review uncovers innovations in incretin therapies, highlighting implications for diabetes treatment.
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair
Multi-omic profiling reveals Retatrutide improves adipose tissue health, suggesting new obesity treatments.
Researchers studying Retatrutide
Researcher network data is loading or unavailable for this topic.
Follow Retatrutide literature with AI-enriched clinical evidence on Synapse.
Search Retatrutide on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers